AstraZeneca ’s AZN second-quarter 2025 core earnings of $1.09 per American depositary share (ADS) came in line with the Zacks ...

Laura McMullin, General Manager, Daiichi Sankyo UK, has been appointed Vice President of the ABPI to support UK life sciences ...

Neha Anand, Analyst, Biopharma Intelligence Services, Citeline, explains how positive Phase III results for Emrelis may position AbbVie as a key player in MET-high non-small cell lung cancer, ...

The Association of the British Pharmaceutical Industry (ABPI) has appointed Laura McMullin as vice president of the trade ...

The triple-negative breast cancer market is expected to grow due to rising incidence rates, increasing awareness, advancements in targeted therapies, ongoing clinical trials, improved diagnostics ...

From concerning statistics on global health outcomes to new insights on AI and RWD, explore the top pharma news from July ...

Bristol Myers will get a nearly 20% stake in the startup, which will be led by one of its former executives and advance five ...

The clinical benefits of exercise-based cardiac rehabilitation have been less clear for patients with Afib. A meta-analysis ...

AbbVie, Bristol Myers Squibb and Eli Lilly appear “relatively well-positioned,” while Novartis and Roche look more at risk, ...

FDA designates T-DXd plus pertuzumab as breakthrough therapy for HER2-positive metastatic breast cancer, promising improved ...

AstraZeneca (AZN) announced Enhertu in combination with pertuzumab has been granted Breakthrough Therapy Designation in the U.S. for the first-line treatment of adult patients with unresectable or ...